Lunit, a leader in AI-powered cancer diagnostics and therapeutics, has partnered with Roche to integrate its Lunit SCOPE PD-L1 22C3 TPS into Roche’s navify® Digital Pathology platform.
This marks the initial deployment of Lunit’s AI technology with Roche, enhancing the tools available to pathologists and researchers and aligning with Roche’s aim to develop a collaborative digital pathology ecosystem.
Roche’s navify® Digital Pathology platform, which enhances the pathologist’s workflow, will now feature Lunit SCOPE alongside its existing AI algorithms.
This integration will offer a comprehensive set of digital pathology tools, advancing biomarker testing and supporting precision medicine to improve patient outcomes.
Initially, the collaboration will focus on the US, with plans to expand into Canada, the EU (UK), Korea, and Japan, reflecting the goal to enhance cancer diagnostics and treatment globally.
Lunit SCOPE PD-L1 22C3 TPS, an AI-powered tool, is designed to analyze the PD-L1 tumor proportion score (TPS), a crucial biomarker in cancer immunotherapy.
By automating the PD-L1 scoring process, it provides more accurate, consistent, and efficient assessments of this complex biomarker.
Since its introduction in 2021 for research use, Lunit SCOPE PD-L1 is now available through Roche’s navify platform, aiming to broaden access to this advanced AI technology.
“They are excited to collaborate with Roche and integrate our AI tools into their digital pathology ecosystem. This partnership is a significant step towards making Lunit’s technology accessible worldwide. Our goal is to advance precision medicine, improve workflow efficiency, and introduce new biomarkers for enhanced patient care.”
Lunit SCOPE PD-L1 TPS is intended for research purposes only and is not approved for diagnostic use.
